Abstract
The validation of a new assay for the leucine degradion product isovaleraldehyde in biological fluids is described. A gas purge technique was used with trapping of volatile constituents in a Tenax cartridge followed by automated thermal desorption and gas chromatographic analysis. The concentration of isovaleraldehyde during the course of hepatic encephalopathy (80 observations in 48 patients; 25 cirrhotic, 23 fulminant hepatic failure) was significantly increased compared to control subjects (0.58 ± 0.08 compared to 0.17 ± 0.02 mol/l; p < 0.001). However, concentrations in grades 3–4 coma (37 observations) and grades 1–2 coma (30 observations) were similar and were not significantly different from values when encephalopathy was absent (grade 0; 13 observations). These results do not support an important role for isovaleraldehyde in the pathogenesis of hepatic encephalopathy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
